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Abstract
Dent’s disease is a renal tubular disorder characterized by manifestations of proximal tubule dysfunction, including
low-molecular-weight proteinuria, hypercalciuria, nephrolithiasis, nephrocalcinosis, and progressive renal failure.
These features are generally found in males only, and may be present in early childhood, whereas female carriers
may show a milder phenotype. Prevalence is unknown; the disorder has been reported in around 250 families to
date. Complications such as rickets or osteomalacia may occur. The disease is caused by mutations in either the
CLCN5 (Dent disease 1) or OCRL1 (Dent disease 2) genes that are located on chromosome Xp11.22 and Xq25,
respectively. CLCN5 encodes the electrogenic Cl
-/H
+ exchanger ClC-5, which belongs to the CLC family of Cl
- chan-
nels/transporters. OCRL1 encodes a phosphatidylinositol bisphosphate (PIP2) 5-phosphatase and mutations are also
associated with Lowe Syndrome. The phenotype of Dent’s disease is explained by the predominant expression of
ClC-5 in the proximal tubule segments of the kidney. No genotype-phenotype correlation has been described thus
far, and there is considerable intra-familial variability in disease severity. A few patients with Dent’s disease do not
harbour mutations in CLCN5 and OCRL1, pointing to the involvement of other genes. Diagnosis is based on the
presence of all three of the following criteria: low-molecular-weight proteinuria, hypercalciuria and at least one of
the following: nephrocalcinosis, kidney stones, hematuria, hypophosphatemia or renal insufficiency. Molecular
genetic testing confirms the diagnosis. The differential diagnosis includes other causes of generalized dysfunction
of the proximal tubules (renal Fanconi syndrome), hereditary, acquired, or caused by exogenous substances.
Antenatal diagnosis and pre-implantation genetic testing is not advised. The care of patients with Dent’s disease is
supportive, focusing on the treatment of hypercalciuria and the prevention of nephrolithiasis. The vital prognosis is
good in the majority of patients. Progression to end-stage renal failure occurs between the 3
rd and 5
th decades of
life in 30-80% of affected males.
Disease name and synonyms
Dent disease 1 (OMIM #300009)
X-linked recessive nephrolithiasis (OMIM #310468)
X-linked recessive hypercalciuric hypophosphataemic
rickets (OMIM #300554)
Low-molecular-weight proteinuria with hypercalciuria
and nephrocalcinosis (OMIM #308990)
Dent disease 2 (OMIM #300555)
Definition and epidemiology
Dent’s disease (OMIM #300009) refers to a heteroge-
neous group of X-linked disorders that have previously
been reported as X-linked recessive nephrolithiasis,
X-linked hypercalciuric hypophosphataemic rickets, or
idiopathic low-molecular-weight proteinuria with
hypercalciuria and nephrocalcinosis [1-6]. The disease is
characterized by manifestations of proximal tubule (PT)
dysfunction associated with hypercalciuria, nephrolithia-
sis, nephrocalcinosis, and progressive renal failure [7].
Low-molecular-weight (LMW) proteinuria represents
the most consistent manifestation of Dent’sd i s e a s e ,
detected in almost all affected males and obligate female
carriers. There is considerable inter- and intra-familial
variability in the other manifestations of PT dysfunction,
which may cause a renal Fanconi syndrome with hypo-
phosphataemic rickets, as well as in the extent of
nephrocalcinosis/nephrolithiasis. Dent’s disease is a rare
disorder, with around 250 affected families reported to
date [8,9].
Clinical description
Dent’s disease is characterized by PT dysfunction and
LMW proteinuria, associated with hypercalciuria,
nephrolithiasis, nephrocalcinosis, and progressive renal
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noaciduria, phosphaturia, glycosuria, uricosuria, kaliur-
esis, and impaired urinary acidification, and is often
complicated by rickets or osteomalacia [4]. These fea-
tures are generally found in males only, who may have
manifestations of the disease from early childhood
[7,8,10]. These patients may present with bone pain and
difficulty in walking due to rickets, or symptoms of
renal stones such as abdominal pain and haematuria.
Occasionally, patients are referred as a result of the for-
tuitous discovery of biological manifestations of PT dys-
function, including LMW proteinuria. LMW
proteinuria, which is characterised by the excretion of
proteins such as a1a n db2 microglobulins, retinol-
binding protein (RBP), Clara cell protein, and vitamin D
binding protein, is found in approximately 99% of
affected males. It has been hypothesized recently that
the urinary loss of RBP may cause episodic night blind-
ness in some patients [11]. Hypercalciuria and nephro-
calcinosis are also highly prevalent and occur in 95%
and 75% of affected males respectively, although there is
considerable inter- and intra-familial variability in the
occurrence of nephrolithiasis which occurs in approxi-
mately 50% of affected males. Progression to end-stage
renal failure occurs between the 3
rd and the 5
th decades
of life in 30-80% of affected males [7]. These manifesta-
tions of Dent’s disease may occur occasionally in
females. For example, the milder features of LMW pro-
teinuria and hypercalciuria are found in approximately
70% and 50% of females carriers, respectively, whilst the
more severe manifestations of nephrolithiasis have been
reported in only 10 females and end-stage renal failure
has been reported in only 1 female [8]. Like other tubu-
lopathies, Dent’s disease has been associated with rare
cases of proteinuria and biopsy-proven focal glomerulo-
sclerosis [12]. The occurrence of these predominantly
renal manifestations and their association with causative
mutations in ClC-5 (see below) is referred to as Dent
disease 1.
Some patients with Dent’s disease have been observed
to have extra-renal manifestations such as mild intellec-
tual impairment [1], hypotonia and cataract, and such
patients have been reported to share mutations in
OCRL1 with the oculo-cerebrorenal syndrome of Lowe
[9,13]. The occurrence of these extra-renal manifesta-
tions with mutations relating to Lowe syndrome is
referred to as Dent disease 2 [13]. To date, around 20
patients with Dent disease 2 have been reported, all of
whom have hypercalciuria and LMW proteinuria. In
addition, these patients may also have nephrocalcinosis,
nephrolithiasis, haematuria, hypophosphataemia and/or
renal insufficiency. Only a minority (approximately one-
fourth) of these patients have been observed to have
mild intellectual deficit, hypotonia and sub-clinical
cataract. It is important to note that the presence of
intellectual impairment and sub-clinical cataract were so
mild as to dissuade the clinicians from considering a
diagnosis of Lowe’s syndrome, which is characterised by
congenital cataracts, delayed motor milestones, some
degree of intellectual impairment in almost all affected
males, growth retardation, rickets and renal proximal
tubulopathy. Moreover, the patients with Dent disease 2
and mild intellectual deficit were adults, who had not,
over time, developed more overt features of Lowe’ss y n -
drome [9,13].
Genetics
Dent’s disease may be caused by either inactivating
mutations in CLCN5 (OMIM #300008), which is located
on chromosome Xp11.22 and encodes a 746 amino-acid
electrogenic Cl
-/H
+ exchanger (ClC-5) [5,14], or the
OCRL1 gene, which is located on chromosome Xq25
and encodes the phosphatidylinositol 4,5-biphosphate
5-phosphatase OCRL1 [13]. ClC-5 contains 18 a-helices,
with two phosphorylation and one N-glycosylation sites.
Structural studies have revealed that the protein forms
diamond-shaped homodimers composed of two repeated
halves that span the membrane in opposite orientations.
Each subunit has its own pore responsible for the selec-
tive coupling of the Cl
- flux to H
+ counter-transport
[15]. The total number of reported CLCN5 mutations is
148, and these are scattered throughout the coding
region, with no evidence for major mutational hot spots
[8]. Furthermore, there appears to be no correlation
between the mutations and phenotypes and/or between
the presence or absence of a CLCN5 mutation and the
Dent’s disease phenotype. Of the total 148 CLCN5
mutations, approximately 36% are nonsense mutations,
33% are missense mutations, 14% are frameshift dele-
tions, 5% are frameshift insertions, 3% are donor splice
site mutations, 3% are acceptor splice site mutations, 2%
are intragenic deletions, 1% are novel splice site muta-
tions, 1% are complete deletions of the gene, 1% are in-
frame insertions, and 1% are in-frame deletions. The
majority are predicted to result in truncated or absent
ClC-5 protein, which would lead to complete loss of
antiporter function. Indeed heterologous expression of
these Dent’sd i s e a s eCLCN5 mutants, in either Xenopus
laevis oocytes or HEK293 cells, has revealed that the
majority of CLCN5 mutations lead to a loss of Cl
- con-
ductance [5]. Further detailed studies of the CLCN5
missense mutations have revealed that these may lead to
one of three abnormalities; endoplasmic reticulum
retention and degradation of ClC-5, defective endosomal
acidification, or altered endosomal distribution of ClC-5
but not defective endosomal acidification [16]. Of note,
the majority of the missense mutations are clustered at
the interface between the two subunits, emphasizing the
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Furthermore, genetic inactivation of the Clcn5 gene in
mice mimics the severe PT dysfunction observed in
Dent’s disease, including hypercalciuria and nephrocalci-
nosis (see below).
Approximately 40% of patients with Dent’sd i s e a s ed o
not have CLCN5 mutations, even though they are clini-
cally indistinguishable from those that have CLCN5
mutations [8]. Twenty of these patients have been
reported to have OCRL1 mutations [9,13], although it is
important to note that none of these had the severe cat-
aracts or intellectual deficit that is typically found in
patients with Lowe syndrome. Consistent with these
phenotypic differences, it is interesting to note that the
OCRL1 mutations associated with Dent disease 2 do not
overlap with those causing Lowe syndrome. All of the
OCRL1 missense mutations associated with Dent’sd i s -
ease occur in the 5’ r e g i o no ft h eg e n e( e x o n s4t o1 5 )
and involve the phosphatidylinositol phosphate 5-
phosphatase domain of the OCRL1 protein, whilst the
truncating mutations are in the first seven exons or
intron 7. By contrast, the OCRL1 mutations that are
found in Lowe syndrome patients occur primarily in
exons 9-22, which encode the 3 large functional
domains [9]. A model in which a reduced but function-
ing form or isoform of OCRL1 protein is expressed in
Dent disease 2, but not Lowe syndrome, has been pro-
posed to explain the milder phenotypic features
observed in the former patients [9]. Thus, there is
genetic heterogeneity for Dent’s disease, with approxi-
mately 50-60% of patients having CLCN5 mutations
(Dent disease 1), ~15% harbouring OCRL1 mutations
(Dent disease 2) and the remaining 25-35% of patients
having neither CLCN5 nor OCRL1 mutations but possi-
bly defects in other genes. The possibility that these
other genes may encode some of the proteins (e.g. ClC-
4 and cofilin) that interact with ClC-5 [18] has been
investigated but no mutations in CLCN4 or COFILIN
were identified [8].
Pathophysiology
The complex phenotype of Dent disease 1 is probably
explained by the predominant expression of ClC-5 in
the PT segments, with more discrete expression in the
thick ascending limb (TAL) of Henle’s loop and the
a-type intercalated cells (IC) of the collecting ducts of
the kidney [19]. In PT cells, ClC-5 co-distributes with
the vacuolar H
+-ATPase (V-ATPase) in early endosomes
[19,20], which are responsible for the reabsorption and
processing of albumin and LMW proteins that are fil-
tered by the glomerulus (Figure 1). These vesicles
belong to the receptor-mediated endocytic pathway,
which involves the multiligand receptors, megalin and
cubilin, located at the apical brush border of PT cells
[21]. Progression along the endocytic apparatus depends
on endosomal acidification, driven by the V-ATPase and
requiring a parallel Cl
- conductance to maintain electro-
neutrality. It has long been assumed that ClC-5 could
provide such an electrical shunt to neutralize the H
+
gradient. Accordingly, the loss of the endosomal Cl
-
conductance mediated by ClC-5 would impair vesicular
acidification, causing dysfunction of PT cells. Two inde-
pendent strains of ClC-5 knock-out (KO) mice have
been generated, which both recapitulate the major fea-
tures of Dent’s disease including LMW proteinuria and
other manifestations of PT dysfunction [22,23]. Further-
more, in vitro experiments have shown a decreased acid-
ification of early endosomes in ClC-5-deficient mice
[24,25].
However, ClC-5 is a 2Cl
-/H
+ exchanger rather than a
Cl
- channel [14], and the relevance of this exchange
activity for Dent’s disease was unknown. To address
that important issue, Jentsch and colleagues engineered
a knock-in (KI) mouse harbouring a point mutation in a
critical glutamate residue which converts the exchanger
into an uncoupled Cl
- channel that should facilitate
endosomal acidification. They then compared these KI
mice with the conventional ClC-5 KO mouse [26]. As
expected, acidification of the renal endosomes from
wild-type and KI mice was normal, but severely
impaired in KO mice. However, despite normal endoso-
mal acidification, KI mice showed the same renal phe-
notype than KO mice and patients with Dent’sd i s e a s e ,
including LMW proteinuria, hyperphosphaturia and
hypercalciuria. Furthermore, both the KI and KO mouse
showed impaired PT endocytosis, indicating that PT
dysfunction in Dent’s disease may occur despite normal
acidification of the endosomes. These findings suggest a
role for a reduced endosomal Cl
- accumulation in
Dent’s disease and, by extension, point to the impor-
tance of Cl
- concentration for organelle physiology [26].
Studies in mice have demonstrated that inactivation of
ClC-5 is associated with a severe trafficking defect in PT
cells, with loss of megalin and cubilin at the brush bor-
der, subsequent loss of their ligands in the urine, and
impaired lysosomal processing [22,23,27]. Since the
megalin/cubilin complex mediates the reabsorption of
the vitamin D-binding protein, the 25(OH)-vitamin D3
and parathyroid hormone (PTH) that are ultrafiltrated
by the glomerulus, the urinary loss of these mediators
could potentially lead to opposite effects in PT cells,
resulting in variable levels of active 1,25(OH)2-vitamin
D3 levels in the serum [28]. Such variability could
explain why renal hypercalciuria and kidney stones are
present in one strain of ClC-5 KO mouse [23] but not
in the other [22], potentially reflecting the phenotype
variability observed in patients harbouring ClC-5 muta-
tions [7]. Recently, Gailly et al. showed that the deletion
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with increased cell proliferation, oxidative stress and the
specific induction of type III carbonic anhydrase [29].
Furthermore, ClC-5 inactivation is associated with
impaired lysosome biogenesis, which also contributes to
defective endocytosis and urinary loss of LMW ligands
and lysosomal enzymes [30]. It must be emphasized that
other inherited disorders targeting the PT cells, such as
lysosomal storage disorders (cystinosis) or mitochondrial
cytopathies, may result in PT dysfunction similar to that
observed in Dent’s disease [31].
The potential roles of ClC-5 in the TAL (involved in
the urinary concentration mechanism and the regulated
reabsorption of divalent cations) [32] and in the a-type
IC (responsible for distal urinary acidification) remain to
be defined [33]. Of interest, CLCN5 mutations have not
been detected in patients with idiopathic hypercalciuria
and in the hypercalciuric stone-forming (GHS) rat strain
[34]. The hypercalciuria observed in patients with Dent’s
disease and some ClC-5-deficient mice may be second-
ary to the PT dysfunction (urinary loss of vitamin D
binding protein and reduced phosphate absorption, lead-
ing to increased 1,25(OH)2-vitamin D3 synthesis) or, at
least in part, caused by the functional loss of ClC-5 in
the TAL. A small fraction of patients with Dent’s disease
may have nephrocalcinosis without hypercalciuria [10],
which could indeed reflect the fact that ClC-5 is distrib-
uted in several nephron segments that can contribute to
the genesis of kidney stones through different mechan-
isms. For instance, it has been suggested that collecting
Figure 1 Role of ClC-5 and pathophysiology of Dent’sd i s e a s e . The epithelial cells lining the proximal tubule segments of the nephron
(boxed area) are characterized by their capacity to reabsorb albumin and low-molecular-weight proteins (LMWP, black dots) that are ultrafiltered
by the glomerulus. The intense endocytic activity in proximal tubule cells involves coated pits and coated vesicles, followed by early endosomes
that form recycling endosomes or mature to late endosomes and lysosomes. Endosomal acidification (up to pH 5.0), that is necessary for
dissociation of the ligand-receptor complex, recycling of receptors to the apical membrane, and progression of ligands into lysosomes, is
achieved by ATP-driven transport of cytosolic H
+ through the V-ATPase. In the apical endosomes, wild-type ClC-5 Cl
-/H
+ exchanger (upper panel)
provides a countercurrent for the proton pump, which facilitates vesicular acidification. In ClC-5 knock-out endosomes (lower panel), the
functional loss of ClC-5 impairs vesicular acidification by accumulating positive charges in the lumen. Defective endocytosis ensues, with a
generalized dysfunction of proximal tubule cells and manifestations of renal Fanconi syndrome.
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internalization of calcium crystals adhering to apical cell
surface [35]. In summary, we can hypothesize that the
functional loss of ClC-5 is essentially reflected by mani-
festations of PT dysfunction and may contribute to the
genesis of kidney stones in different ways, reflecting its
involvement in specific tubular functions. The issue is
further complicated by the existence of a significant
inter- and intra-familial variability in the manifestations
of nephrocalcinosis and kidney stones.
Although ClC-5 mRNA and protein are detected in
rodent intestine [36] and thyroid [37], no clear pheno-
type related to these tissues has been reported in
patients. Of note, ClC-5 is highly expressed in the
mouse thyroid, located in various endosomes at the api-
cal pole of the thyrocytes. Mice lacking ClC-5 develop a
euthyroid goiter, which results from impaired apical
iodide efflux (secondary to down-regulated pendrin)
rather than defective apical endocytosis [37].
The phenotype of Dent disease 2 due to OCRL1 muta-
tions may in part be attributed to the role of OCRL1 in
lysosomal trafficking and endosomal sorting. OCRL1
encodes a member of the type II family if inositol poly-
phosphate 5-phosphatases [38]. These enzymes hydro-
lyze the 5-phosphate of inositol 1, 4, 5-trisphosphate
and of inositol 1,3,4,5-tetrakisphosphate, phosphatidyli-
nositol 4,5-bisphosphate, and phosphatidylinositol 3,4,5-
trisphosphate, thereby presumably inactivating them as
second messengers in the phosphatidylinositol signalling
pathway [39]. The preferred substrate of OCRL1 is
phosphatidylinositol 4,5-bisphosphate (PIP2), and this
lipid accumulates in the renal PT cells of patients with
Lowe syndrome [39]. OCRL1 is localised to lysosomes
in renal PT cells and to the trans-Golgi network in
fibroblasts. This localisation is consistent with the role
of OCRL1 in lysosomal enzyme trafficking from the
trans-Golgi network to lysosomes, and the activities of
several lysosomal hydrolases are found to be elevated in
the plasma of affected patients [40]. OCRL1 has also
been shown to interact with clathrin and indeed co-
localises with clathrin on endosomal membranes that
contain tranferrin and mannose 6-phosphate receptors
[41]. Mannose 6-phosphate receptor-bound lysosomal
enzymes are recruited by appendage (AP) subunits and
Golgi-localised binding proteins into clathrin-coated
vesicles that transport themf r o mt h et r a n s - G o l g in e t -
work to endosomes [41]. More recently, Erdmann et al.
showed that OCRL1 plays a role in the early endocytic
pathway, by interacting with the Rab5 effector APPL1
[42]. Thus, it seems likely that the OCRL1 mutations in
Lowe syndrome patients result in OCRL1 protein defi-
ciency, which leads to disruptions in the endosomal
and/or lysosomal trafficking. This abnormality is similar
to that observed in Dent disease 1, and it seems that
Dent’s disease therefore may be due to abnormalities in
either endosomal acidification and sorting, or lysosomal
trafficking. It must be noted that the targeted disruption
of the murine ortholog for OCRL1 does not cause Lowe
syndrome, because Ocrl1 deficiency is complemented in
mice by inositol polyphosphate 5-phosphatase (Inpp5b)
[43]. Thus, no mouse model recapitulating Lowe syn-
drome caused by the deficiency in OCRL1 is available.
Diagnosis
The clinical diagnosis of Dent’s disease is based on the
presence of all three of the following criteria: (i) LMW
proteinuria (elevation of urinary excretion of b2-
microglobulin, Clara cell protein and/or RBP by at least
5-fold above the upper limit of normality); (ii) hypercal-
ciuria (> 4 mg/kg in a 24 h-hour collection or > 0.25
mg Ca
2+ per mg creatinine on a spot sample); and (iii)
at least one of the following: nephrocalcinosis, kidney
stones, hematuria, hypophosphataemia, or renal insuffi-
ciency. The clinical diagnosisi ss u p p o r t e db yah i s t o r y
of X-linked inheritance of renal Fanconi syndrome and/
or nephrolithiasis. The identification of mutation in
either CLCN5 or OCRL1 confirms the diagnosis. How-
ever, some patients with CLCN5 mutations have been
reported to have LMW proteinuria or hypercalciuria
a l o n e[ 3 4 , 4 4 ] ,a n dt h u si nt h ep r e s e n c eo fa ni d e n t i f i e d
CLCN5 mutation, only one of the above clinical criteria
may be sufficient to establish an affected status in an
individual. It is important to note that the absence of
clinical cataracts and the lack of severe intellectual defi-
cit are key features that make a diagnosis of Dent dis-
ease 2, associated with OCRL1 mutations, more likely
than a diagnosis of Lowe syndrome.
There have been few reports of renal biopsies in cases
with proven CLCN5 mutations [45]. Light microscopy
studies revealed progressive, non-specific lesions that
include glomerular hyalinosis, tubular cell degeneration
or atrophy, and mild interstitial fibrosis. Of interest,
these kidneys invariably showed hyaline casts that were
sometimes calcified, located in the outer medulla and
presumably the first manifestations of nephrocalcinosis.
By contrast, electron microscopy did not reveal any
ultrastructural abnormalities in PT cells [45].
Differential diagnosis
The differential diagnosis of Dent’s disease includes the
other causes of generalized PT dysfunction (renal Fan-
coni syndrome), that can be inherited, acquired or
caused by exogenous substances [31,46] (Appendix 1).
Genetic counselling
Both forms of Dent’s disease are X-linked, and males,
who are hemizygous, are affected more severely.
Females, who are usually only mildly affected, are
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sons whereas half of their daughters will be carriers. All
the daughters of affected males will be carriers as they
will have inherited the X chromosome harbouring the
mutation, but all the sons of affected fathers who will
have inherited the Y chromosome and not the X chro-
mosome, will be normal. In approximately 10% of
patients, Dent’s disease occurs de novo and a family his-
tory is absent, but the disease will be transmitted as an
X-linked trait to subsequent generations. If the mother
or siblings of a patient with Dent’s disease are eager to
know their genetic status and risk for developing the
disease, then mutational analysis of CLCN5 and/or
OCRL1, using leukocyte DNA can be undertaken. How-
ever, it is important to note that it may not be routinely
available in all genetic diagnostic laboratories. Although
technically feasible, antenatal diagnosis and pre-implan-
tation genetic testing for Dent’s disease is not advised,
and as yet has not been requested, because the vital
prognosis in the majority of patients is good and there
is no evidence for a genotype-phenotype correlation.
Indeed the severity of the disease may vary considerably
in individuals from the same family [10,34,47].
Treatment
In the absence of therapy targeting the molecular defect,
the current care of patients with Dent’s disease is suppor-
tive, focusing on the prevention of nephrolithiasis. Thia-
zide diuretics can be used to treat hypercalciuria [48,49]
although significant adverse events, including hypovole-
mia and hypokalemia related to the primary tubulopathy,
have been reported [49]. Similarly, treatment of rickets
with vitamin D must be cautious since it may increase
hypercalciuria. Studies performed on ClC-5-deficient
mice suggest that long-term control of hypercalciuria by
a high citrate diet delays progression of renal disease
even in the apparent absence of stone formation [50].
Conclusions
Dent’s disease is a renal tubular disorder caused by
mutations in either the CLCN5 (Dent disease 1) or
OCRL1 (Dent disease 2) genes that are located on chro-
mosome Xp11.22 and Xq25, respectively. CLCN5
encodes the electrogenic Cl
-/H
+ exchanger ClC-5, which
is primarily located in the endosomes of the PT cells.
The pathophysiology of the disease is essentially due to
defective receptor-mediated endocytosis causing a gen-
eralized dysfunction of PT cells. OCRL1 encodes a PIP2
5-phosphatase and mutations are also associated with
the oculo-cerebro-renal syndrome of Lowe, character-
ized by bilateral congenital cataract, severe mental retar-
dation, and renal Fanconi syndrome. A few patients
with Dent’s disease do not harbour mutations in CLCN5
and OCRL1, pointing to the involvement of other genes.
The care of patients with Dent’s disease is supportive,
focusing on the prevention of nephrolithiasis. The cau-
tious use of thiazide diuretics has been suggested to
treat the associated hypercalciuria.
Appendix 1. Differential diagnosis of Dent’s
disease: causes of renal Fanconi syndrome
Inherited disorders
Dent disease
Lowe syndrome
Cystinosis
Galactosemia
Hereditary fructose intolerance
Glycogen storage disease (von Gierke disease)
Fanconi-Bickel syndrome
Tyrosinemia type I
Wilson disease
Mitochondrial diseases (cytochrome-c oxidase
deficiency)
Idiopathic Fanconi syndrome
Sporadic Fanconi syndrome
Acquired disorders
Glomerular proteinuria (nephrotic syndrome)
Light chain nephropathy (multiple myeloma)
Sjögren syndrome
Auto-immune interstitial nephritis
Acute tubulo-interestitial nephritis with uveitis
(TINU)
Renal transplantation
Anorexia nervosa
Exogenous substances
Drugs
Aminoglycosides, outdated tetracycline
Valproate, salicylate
Adefovir, cidofovir, tenofovir
Ifosfamide, cisplatin, imanitib mesylate
Chinese herbs (aristolochic acid)
Chemical compounds (paraquat, diachrome, 6-mer-
captopurine, toluene, maleate)
Heavy metals (lead, cadmium, chromium, platinum,
uramnium, mercury)
Abbreviations
IC: intercalated cell; LMW:low-molecular-weight; PIP2: phosphatidylinositol
[45] bisphosphate; PT: proximal tubule; PTH: parathyroid hormone; RBP:
retinol binding protein; TAL: thick ascending limb (of Henle’s loop); V:
ATPase; vacuolar H
+-ATPase
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